Merck stock dipped more than 4% in morning trading_老虎社区_美港股上老虎

Merck stock dipped more than 4% in morning trading

Tiger Newspress2021-11-29

Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.

Disappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.

Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.

“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.

Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

200

Huatkor
·2021-11-30
Don’t worry. It is a good company even without the covid drug.
回复
1
举报
收起
- AndrewL:
  Ok
  2021-11-30
  回复
  举报
TSY123
·2021-11-30
Ok
回复
1
举报
Juanlee
·2021-11-30
Merck pill was reported to have a lower effectiveness than announced.
回复
2
举报
ArcherWG
·2021-11-30
👌🏻
回复
3
举报
ShenGY
·2021-11-30
Sad
回复
1
举报
收起
- ArcherWG:
  Mm
  2021-11-30
  回复
  举报
MengKeng
·2021-11-30
It will be a good time for us to buy, let's monitor and then buy low, sell high. Haha
回复
2
举报
收起
- sunshine138:
  Haha
  2021-11-30
  回复
  举报
seojun
·2021-11-30
Oh no!
回复
2
举报
Blake316
·2021-11-30
Sad
回复
2
举报
AAPL1218
·2021-11-29
sad[Cry]
回复
2
举报
JovRene
·2021-11-29
Ok
回复
3
举报
Minz98
·2021-11-29
Please like
回复
4
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-11-30
  回复
  举报
- Desoupie:
  Ok
  2021-11-30
  回复
  举报
ivlee
·2021-11-29
What is this sorcery
回复
4
举报
收起
- seojun:
  sigh
  2021-11-30
  回复
  举报
- mistyzenz:
  oh
  2021-11-29
  回复
  举报
Haw75
·2021-11-29
Latest
回复
7
举报
收起
- 51c4c89:
  Ok
  2021-11-29
  回复
  举报
lost0star
·2021-11-29
Okay
回复
8
举报
收起
- lost0star:
  okay
  2021-11-29
  回复
  举报
HoSeyLiao48
·2021-11-29
[冷漠] [可怜] [叹气] [疑问] [心碎]
回复
11
举报
收起
- Footixx:
  😩
  2021-11-29
  回复
  举报
LimHianYew
·2021-11-29
Why?
回复
7
举报
收起
- SiewLooiWan:
  sure
  2021-11-29
  回复
  举报
- LimHianYew:
  Very bad
  2021-11-29
  回复
  举报
Chillman
·2021-11-29
Wow
回复
8
举报
收起
- Wheee:
  amazing
  2021-11-29
  回复
  举报
Qwer1234
·2021-11-29
Ok
回复
7
举报
收起
- Chillman:
  Ok
  2021-11-29
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-29 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137393357","market":"us","top_or_hot":-1,"title":"Merck stock dipped more than 4% in morning trading","media":"Tiger Newspress","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p>\n<p><img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p>\n<p>Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p>\n<p>“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p>\n<p>Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n2021-11-29 22:49 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":null,"article_id":"1137393357","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","pubTimestamp":1638197348,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"默沙东股市早盘下跌逾4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":609934684,"gmtCreate":1638230483028,"gmtModify":1638237167557,"author":{"id":"3581919183376534","authorId":"3581919183376534","name":"Huatkor","avatar":"https://static.tigerbbs.com/6f3897aace055b5fa9f58089c1e880d8","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3581919183376534","idStr":"3581919183376534"},"htmlText":"Don’t worry.&nbsp;It is a good company even&nbsp;without the covid drug.&nbsp;&nbsp;","listText":"Don’t worry.&nbsp;It is a good company even&nbsp;without the covid drug.&nbsp;&nbsp;","text":"Don’t worry. It is a good company even without the covid drug.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609934684","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6780116,"gmtCreate":1638243189348,"gmtModify":1638243189452,"authorId":3571815908504020,"author":{"id":3571815908504020,"idStr":"3571815908504020","authorId":3571815908504020,"name":"AndrewL","avatar":"https://static.tigerbbs.com/f45655eaaab14f0b61c554eea4d95ca7","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":609934684,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":609993919,"gmtCreate":1638229546921,"gmtModify":1638229829509,"author":{"id":"3583665662213187","authorId":"3583665662213187","name":"TSY123","avatar":"https://static.tigerbbs.com/af38fbc4f07efb7ae9b5ebd03aa4b79b","vip":1,"crmLevel":13,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3583665662213187","idStr":"3583665662213187"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609993919","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609905474,"gmtCreate":1638229289196,"gmtModify":1638229289656,"author":{"id":"3553595575003751","authorId":"3553595575003751","name":"Juanlee","avatar":"https://static.tigerbbs.com/fbf36c4a5cfcee186a3187df34efc7f9","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3553595575003751","idStr":"3553595575003751"},"htmlText":"Merck pill was reported to have a lower effectiveness than announced.&nbsp;","listText":"Merck pill was reported to have a lower effectiveness than announced.&nbsp;","text":"Merck pill was reported to have a lower effectiveness than announced.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609905474","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609076483,"gmtCreate":1638228581347,"gmtModify":1638228582781,"author":{"id":"3581837121803380","authorId":"3581837121803380","name":"ArcherWG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3581837121803380","idStr":"3581837121803380"},"htmlText":"👌🏻&nbsp;","listText":"👌🏻&nbsp;","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609076483","repostId":1137393357,"repostType":2,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609045413,"gmtCreate":1638228090236,"gmtModify":1638228090354,"author":{"id":"4099261143755430","authorId":"4099261143755430","name":"ShenGY","avatar":"https://static.tigerbbs.com/e3a5b601d7373e94cf8257ec4aec4f52","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"4099261143755430","idStr":"4099261143755430"},"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609045413","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6775448,"gmtCreate":1638228564281,"gmtModify":1638228564389,"authorId":3581837121803380,"author":{"id":3581837121803380,"idStr":"3581837121803380","authorId":3581837121803380,"name":"ArcherWG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":609045413,"type":1,"supId":0,"prevId":0,"content":"<u>Mm</u>","text":"<u>Mm</u>","html":"<u>Mm</u>"}],"langContent":"CN"},{"id":609042127,"gmtCreate":1638227970396,"gmtModify":1638227971293,"author":{"id":"3582668988155006","authorId":"3582668988155006","name":"MengKeng","avatar":"https://static.tigerbbs.com/daf999525f61ba41d3c13b0ed728eb77","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3582668988155006","idStr":"3582668988155006"},"htmlText":"It will be a good time for us to buy, let's monitor and then buy low, sell high. Haha","listText":"It will be a good time for us to buy, let's monitor and then buy low, sell high. Haha","text":"It will be a good time for us to buy, let's monitor and then buy low, sell high. Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609042127","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6775357,"gmtCreate":1638228363757,"gmtModify":1638228363787,"authorId":3586655655659820,"author":{"id":3586655655659820,"idStr":"3586655655659820","authorId":3586655655659820,"name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":609042127,"type":1,"supId":0,"prevId":0,"content":"<u>Haha</u>","text":"<u>Haha</u>","html":"<u>Haha</u>"}],"langContent":"CN"},{"id":609085330,"gmtCreate":1638222230552,"gmtModify":1638222231687,"author":{"id":"4087771643270940","authorId":"4087771643270940","name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"4087771643270940","idStr":"4087771643270940"},"htmlText":"Oh no!","listText":"Oh no!","text":"Oh no!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609085330","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600774776,"gmtCreate":1638202109005,"gmtModify":1638202545924,"author":{"id":"4101294624300960","authorId":"4101294624300960","name":"Blake316","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"4101294624300960","idStr":"4101294624300960"},"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600774776","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600757714,"gmtCreate":1638200102662,"gmtModify":1638200102797,"author":{"id":"3581768776429785","authorId":"3581768776429785","name":"AAPL1218","avatar":"https://static.tigerbbs.com/ba863bd38fca4e924e6722519bf62a8e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3581768776429785","idStr":"3581768776429785"},"htmlText":"sad[Cry]&nbsp;","listText":"sad[Cry]&nbsp;","text":"sad[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600757714","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600756085,"gmtCreate":1638199780339,"gmtModify":1638199800946,"author":{"id":"4095072535386190","authorId":"4095072535386190","name":"JovRene","avatar":"https://static.tigerbbs.com/cc1c4680fc5d92b0cbb4f5ea0eadaa83","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"4095072535386190","idStr":"4095072535386190"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600756085","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600722486,"gmtCreate":1638199304062,"gmtModify":1638199304150,"author":{"id":"3582803159303555","authorId":"3582803159303555","name":"Minz98","avatar":"https://static.tigerbbs.com/2d2093834aabec0c8de1bff4779af70e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3582803159303555","idStr":"3582803159303555"},"htmlText":"Please like&nbsp;","listText":"Please like&nbsp;","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600722486","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6775134,"gmtCreate":1638227682991,"gmtModify":1638227683092,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600722486,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6774233,"gmtCreate":1638223255652,"gmtModify":1638223255758,"authorId":4088779006345160,"author":{"id":4088779006345160,"idStr":"4088779006345160","authorId":4088779006345160,"name":"Desoupie","avatar":"https://static.tigerbbs.com/61605302726ca838436e74d61cb437ae","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600722486,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":600760718,"gmtCreate":1638198327282,"gmtModify":1638198367105,"author":{"id":"3578202423402750","authorId":"3578202423402750","name":"ivlee","avatar":"https://static.tigerbbs.com/a499a1abe0e3686d1a9dcf0cc47d5224","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3578202423402750","idStr":"3578202423402750"},"htmlText":"What is this sorcery","listText":"What is this sorcery","text":"What is this sorcery","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600760718","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6774025,"gmtCreate":1638222270320,"gmtModify":1638222270431,"authorId":4087771643270940,"author":{"id":4087771643270940,"idStr":"4087771643270940","authorId":4087771643270940,"name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600760718,"type":1,"supId":6772303,"prevId":0,"content":"sigh","text":"sigh","html":"sigh"},{"id":6772303,"gmtCreate":1638198764817,"gmtModify":1638198764884,"authorId":3561962801944040,"author":{"id":3561962801944040,"idStr":"3561962801944040","authorId":3561962801944040,"name":"mistyzenz","avatar":"https://static.tigerbbs.com/b6ce5e71746857498b3364479f136e14","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600760718,"type":1,"supId":0,"prevId":0,"content":"<u>oh</u>","text":"<u>oh</u>","html":"<u>oh</u>"}],"langContent":"CN"},{"id":600787436,"gmtCreate":1638198258983,"gmtModify":1638198260694,"author":{"id":"3580379447244817","authorId":"3580379447244817","name":"Haw75","avatar":"https://static.tigerbbs.com/b8a435feb2331b895463eca3c73cdb3f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3580379447244817","idStr":"3580379447244817"},"htmlText":"Latest&nbsp;","listText":"Latest&nbsp;","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600787436","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6772161,"gmtCreate":1638198385100,"gmtModify":1638198385130,"authorId":3577087072632041,"author":{"id":3577087072632041,"idStr":"3577087072632041","authorId":3577087072632041,"name":"51c4c89","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600787436,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":600784917,"gmtCreate":1638198149983,"gmtModify":1638198204060,"author":{"id":"3577931905567659","authorId":"3577931905567659","name":"lost0star","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3577931905567659","idStr":"3577931905567659"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600784917","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6772084,"gmtCreate":1638198153762,"gmtModify":1638198153788,"authorId":3577931905567659,"author":{"id":3577931905567659,"idStr":"3577931905567659","authorId":3577931905567659,"name":"lost0star","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600784917,"type":1,"supId":0,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"}],"langContent":"CN"},{"id":600786960,"gmtCreate":1638197990281,"gmtModify":1638197995468,"author":{"id":"4087949413245130","authorId":"4087949413245130","name":"HoSeyLiao48","avatar":"https://static.tigerbbs.com/8a9a7795aa16cbb122ca86630c428a3a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"4087949413245130","idStr":"4087949413245130"},"htmlText":"[冷漠]&nbsp;[可怜]&nbsp;[叹气]&nbsp;[疑问]&nbsp;[心碎]&nbsp;","listText":"[冷漠]&nbsp;[可怜]&nbsp;[叹气]&nbsp;[疑问]&nbsp;[心碎]&nbsp;","text":"[冷漠] [可怜] [叹气] [疑问] [心碎]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600786960","repostId":1137393357,"repostType":2,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6772080,"gmtCreate":1638198137679,"gmtModify":1638198137708,"authorId":3572228950547010,"author":{"id":3572228950547010,"idStr":"3572228950547010","authorId":3572228950547010,"name":"Footixx","avatar":"https://static.tigerbbs.com/286a694c51da40f13325f2f7cd6b8851","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600786960,"type":1,"supId":0,"prevId":0,"content":"😩","text":"😩","html":"😩"}],"langContent":"CN"},{"id":600714784,"gmtCreate":1638197640853,"gmtModify":1638197641505,"author":{"id":"3576363559636103","authorId":"3576363559636103","name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3576363559636103","idStr":"3576363559636103"},"htmlText":"Why?","listText":"Why?","text":"Why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600714784","repostId":1137393357,"repostType":2,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6772273,"gmtCreate":1638198679627,"gmtModify":1638198679725,"authorId":3582061758353540,"author":{"id":3582061758353540,"idStr":"3582061758353540","authorId":3582061758353540,"name":"SiewLooiWan","avatar":"https://static.tigerbbs.com/882a76fb2f3809d087f6c6ad77073f77","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600714784,"type":1,"supId":6771952,"prevId":0,"content":"<u>sure</u>","text":"<u>sure</u>","html":"<u>sure</u>"},{"id":6771952,"gmtCreate":1638197662902,"gmtModify":1638197662929,"authorId":3576363559636103,"author":{"id":3576363559636103,"idStr":"3576363559636103","authorId":3576363559636103,"name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600714784,"type":1,"supId":0,"prevId":0,"content":"Very bad","text":"Very bad","html":"Very bad"}],"langContent":"CN"},{"id":600712164,"gmtCreate":1638197517725,"gmtModify":1638197518092,"author":{"id":"3558275010133966","authorId":"3558275010133966","name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3558275010133966","idStr":"3558275010133966"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600712164","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6772086,"gmtCreate":1638198161514,"gmtModify":1638198161616,"authorId":3580123620847057,"author":{"id":3580123620847057,"idStr":"3580123620847057","authorId":3580123620847057,"name":"Wheee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600712164,"type":1,"supId":0,"prevId":0,"content":"amazing","text":"amazing","html":"amazing"}],"langContent":"CN"},{"id":600716161,"gmtCreate":1638197462275,"gmtModify":1638197462689,"author":{"id":"3572867061700089","authorId":"3572867061700089","name":"Qwer1234","avatar":"https://static.tigerbbs.com/4f048323098795168028c3aee02d87a4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"wearingBadges":[],"authorIdStr":"3572867061700089","idStr":"3572867061700089"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600716161","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohunote.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌超过 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p><p><blockquote>默克股价在早盘交易中下跌超过 4%，花旗研究将其评级从买入下调至中性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物的业绩令人失望，限制了默克股价的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁-鲍姆（Andrew Baum）将默克公司的评级从买入下调至中性，并在周一给客户的一份报告中称，该公司艾滋病毒药物伊斯拉曲韦的开发困境正在蚕食默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对 MRK 的长期投资论点是基于对 MRK 产品线的低估，尤其是治疗艾滋病毒的 islatravir，以帮助抵消即将到来的 Keytruda（排他性丧失）......我们已从模型中删除了 2030 年 40 亿美元风险调整后的预期，将每股收益预期降低了 10%，”报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克公司的目标价从每股 105 美元下调至 85 美元。新目标比该股周五收盘价高出约 7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6771914,"gmtCreate":1638197525318,"gmtModify":1638197525423,"authorId":3558275010133966,"author":{"id":3558275010133966,"idStr":"3558275010133966","authorId":3558275010133966,"name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":600716161,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":200,"commentSize":18,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}